Astellas Splits Sales Emerging Growth In Russia And China, But A Late Entry To India May Soon Be Rewarded
This article was originally published in The Pink Sheet Daily
Executive Summary
Astellas outlines its growth strategy, offering ways the company plans to overcome the sales loss of U.S. patent expiries for blockbusters Prograf (tacrolimus) and Harnal (tamsulosin).
You may also be interested in...
From Product Launches To Toll Manufacturing, Japanese Giant Takeda Unveils Plans For India
MUMBAI - Almost a year after naming former Roche executive Shankar Suryanarayanan as head of its Indian operations, Japan's largest drug maker Takeda has unveiled "medium- to long-term strategies" for its business expansion - one of which is to launch its products in the burgeoning Indian market
Indian Companies Are Becoming More Creative, Says Astellas India Managing Director Teruo Yasufuku: An Interview With PharmAsia News
Teruo Yasufuku, managing director for Astellas Pharma India, is soft-spoken and carefully measures every answer that he shares with the media. But the law graduate who started his career as a medical representative with Fujisawa in 1983 has been recognized for his leadership skills and the enthusiasm to be the best in the business. Terry, as he is called by his Indian industry contemporaries, can tirelessly talk about Prograf (tacrolimus) - Astellas' flagship transplant brand that notches worldwide sales upwards of $2 billion many years after it has been copied by generic companies. Yasufuku, along with his marketing director Himanshu Dave, proudly point at the back of their business cards, which say 'I Pledge To Donate - kidney, liver, heart, lung, pancreas, corneas.' This, Yasufuku asserts, is Astellas' unflinching commitment to the transplant segment. And, although it is a late entrant and faces intense generic competition, Prograf has a long roadmap laid out for growth in India. Yasufuku shares his wide angle on Astellas' India strategy with PharmAsia News India bureau.
Astellas Completes OSI Acquisition; Shares Jump In Tokyo
Astellas announced the completion of its acquisition of OSI Pharmaceuticals, obtaining 93 percent of OSI Pharmaceuticals' publicly traded shares. The New York-based company immediately became a wholly owned subsidiary of Astellas U.S. Holding